At a glance
Phase 1 including first-in-human clinical trials to test biomarker-guided medicines or multi-modal treatment interventions for patients with rare or very rare cancers or cancer subtypes is an EU-level competitive grant from European Commission for the horizon europe sector. Eligible applicants: Open to eligible organisations in EU Member States and Horizon Europe associated countries; consortium requirements vary by topic - see the official call conditions. The application deadline is September 21, 2027. Apply via the official listing at ec.europa.eu.
- Amount
- See listing
- Deadline
- Sep 21, 2027
- Type
- Competitive
- Status
- Forecasted
About this program
See the official listing for full program detail.
Who can apply
Open to eligible organisations in EU Member States and Horizon Europe associated countries; consortium requirements vary by topic - see the official call conditions.
How to apply
Apply through the EU Funding & Tenders portal; submission is electronic via the portal's Submission Service before the topic deadline.
Apply at official source